Scientific Publications and Educational Resources on Endothelial Cell Therapy

Publications

Explore peer-reviewed research, clinical findings, and global perspectives on corneal endothelial disease and cell-based therapeutic approaches. These publications provide foundational insights into the science informing Aurion Biotech’s work.

Cornea

December 2025

ESCALÓN: A Prospective Randomized Trial of Corneal Endothelial Cell Therapy in Subjects With Corneal Edema

JAMA Ophthalmology

October 18, 2025

Global Survey of Corneal Transplantation & Eye Banking

National Library of Medicine

May 29, 2025

Long-term Corneal Rejuvenation after Transplantation of Cultured Human Corneal Endothelial Cells

JAMA Ophthalmology

July 25, 2024

Guttae Morphology After Cultured Corneal Endothelial Cell Transplant in Fuchs Endothelial Corneal Dystrophy

Corneal Physician

April 8, 2022

Injectable Corneal Endothelial Cells

AAO Ophthalmology Journal:

September 1, 2020

Five-Year Follow-up...Cultured Corneal Endothelial Cells

The New England Journal of Medicine

March 15, 2018

Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy

Frequently Asked Questions

Find answers to common questions about corneal endothelial disease, current treatment options, and Aurion Biotech’s ongoing clinical development efforts.

What is the corneal endothelium and why is it important?

The corneal endothelium is composed of a single layer of cells lining the posterior surface of the cornea. These cells regulate fluid balance to maintain corneal clarity, which is essential for vision. Because endothelial cells do not regenerate, their loss leads to swelling, clouding, and progressive visual decline.

What is corneal endothelial dysfunction?

Endothelial dysfunction occurs when endothelial cells degrade or are lost due to conditions such as Fuchs dystrophy, congenital dystrophies, age-related decline, or surgical trauma. As the cornea becomes edematous, patients may experience blurred vision, glare, reduced contrast, discomfort, or significant pain.

How is endothelial dysfunction currently treated?

Early symptoms may be managed with topical therapies to reduce swelling.
More advanced disease typically requires corneal transplantation, including:

PK (Penetrating Keratoplasty) – full-thickness transplant
DSAEK / DMEK (Endothelial Keratoplasty) – selective replacement of the posterior cornea and endothelial layer

While effective, these procedures depend on donor tissue and specialized surgical expertise.

How did Vyznova^®’s early development shape today’s program?

Vyznova was originally invented and first clinically developed in Japan. Aurion Biotech later acquired the rights to the therapy after substantial research and clinical experience had already been established through the pioneering work of Professor Shigeru Kinoshita and colleagues. This early development enabled regulatory approval in Japan and provided the foundation for Aurion’s subsequent clinical development programs in the United States and other regions.

Is Aurion’s cell therapy available today?

Aurion’s cell therapy is fully approved and has been commercialized in Japan since late 2024. In the US, Aurion Biotech has concluded its Phase I/II clinical trial in the U.S. and Canada. Phase III clinical trial is targeted to initiate enrollment in H1 of 2026.

How can I stay informed about Aurion Biotech?

Explore More from Aurion Biotech

For press releases, updates, and the latest company announcements, visit our News page.